21. Neuroendocrine carcinoma of the larynx and pharynx : a clinical and histopathological studyPrimož Strojan, Robert Šifrer, Alfio Ferlito, Cvetka Grašič-Kuhar, Boštjan Lanišnik, Gaber Plavc, Nina Zidar, 2021, original scientific article Abstract: Neuroendocrine carcinomas (NECs) of the head and neck are rare and the experience scanty. The Cancer Registry of Slovenia database was used to identify cases of laryngeal and pharyngeal NECs diagnosed between 1995%2020. Biopsies were analyzed for the expression of standard neuroendocrine markers (synaptophysin, chromogranin, CD56), INSM1, Ki-67, p16, and PD-L1 (using the combined positive score, CPS). In situ hybridization for human papillomavirus (HPV) and Epstein%Barr virus (EBV) was performed. Twenty patients (larynx, 12; pharynx, 8) were identified. One tumor was well differentiated (WD), five were moderately differentiated (MD), and 14 were poorly differentiated (PD). Disease control was achieved solely by surgery in 4/4 MD/PD T1-2N0-1 tumors. Eight patients died of the disease, seven of which were due to distant metastases. All three traditional markers were positive in 11/17 NECs and the INSM1 marker in all 20 tumors. Two of fourteen p16-positive tumors were HPV-positive, but all three nasopharyngeal NECs were EBV-negative. Three tumors had CPSs % 1. In conclusion, INSM1 was confirmed to be a reliable marker of neuroendocrine differentiation. Except in WD and early-stage MD/PD tumors, aggressive multimodal therapy is needed; the optimal systemic therapy remains to be determined. p16, HPV, and EBV seem to bear no prognostic information. Keywords: electrochemotherapy, head and neck cancer, neuroendocrinic carcinoma Published in DiRROS: 07.09.2022; Views: 559; Downloads: 252 Full text (3,97 MB) This document has many files! More... |
22. V pomoč pri zdravljenju diferenciranega raka ščitnice, odpornega na radioaktivni jod, z zdravilom lenvatinib2022, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: rak ščitnice, kemoterapija, lenvatinib Published in DiRROS: 14.07.2022; Views: 591; Downloads: 185 Full text (550,94 KB) |
23. Stališča onkologov o bolniški odsotnosti bolnic z rakom dojk, ki so v delovnem razmerjuIvica Ratoša, Cvetka Grašič-Kuhar, 2022, original scientific article Abstract: Izhodišče: Optimizacija rehabilitacije onkoloških bolnikov in njihova vrnitev na delo sta pomembni tako zaradi izboljšanja počutja te ranljive skupine kot tudi zaradi zmanjšanja družbenih in finančnih vplivov na celotno družbo. Osebe, ki so prebolele raka, se poskušajo po zdravljenju vrniti na delo in znova vzpostaviti nekdanjo strukturo vsakdanjega življenja. Z raziskavo smo želeli razkriti stališča onkologov do bolniške odsotnosti bolnic z rakom dojk. Metode: Med slovenskimi onkologi, ki sodelujejo pri zdravljenju bolnic z rakom dojk, smo izvedli krajšo anonimno spletno anketo o stališčih do bolniške odsotnosti omenjenih bolnic. Rezultati: Na spletno anketo je od 52 povabljenih onkologov odgovorilo 24 (46,2 %), od tega 8 (33,3 %) specialistov internistične onkologije, 9 (37,5 %) specialistov onkologije z radioterapijo in 7 (29,2 %) specialistov kirurgov. Stališče onkologov, ocenjeno z 10-stopenjsko Likertovo lestvico, je, da sta pogovor z bolnico in obravnava vprašanj o vrnitvi na delovno mesto zelo pomemben del celostne obravnave (povprečna ocena 8,4/10). Hkrati pa ocenjujejo, da je razmerje med časom, ki ga imajo vsakodnevno na voljo za obravnavo bolnic z rakom dojk, in časom, ki ga lahko posvetijo vprašanjem o bolniški odsotnosti med zdravljenjem ali po zaključenem zdravljenju, slabo (povprečna ocena 3,6/10). Sorazmerno pogosto se srečujejo s t. i. pritiski bolnic zaradi podajanja mnenj v zvezi z bolniško odsotnostjo ali invalidsko upokojitvijo (povprečna ocena 6,5/10). V vprašalniku so bili prav tako zbrani predlogi za dolžino bolniškega staleža, upoštevajoč vrsto in zahtevnost zdravljenja ter individualne dejavnike. Predlagana je bila skupina strokovnjakov, ki bi sestavljala multidisciplinaren tim za obravnavo bolnic z bolniškim staležem Keywords: rak dojke, zdravljenje, bolniška odsotnost, rehabilitacija Published in DiRROS: 01.07.2022; Views: 1162; Downloads: 239 Full text (215,07 KB) |
24. Posodobljena priporočila diagnostike in zdravljenja diferenciranega raka ščitniceNikola Bešić, Alenka Grošel, Andraž Perhavec, Andrej Doma, Andreja A. Schwarzbartl-Pevec, Andreja Klevišar Ivančič, Andrej Vogrin, Barbara Vidergar-Kralj, Barbara Gazić, Barbara Perić, Blaž Krhin, Cvetka Grašič-Kuhar, Edvard Pirnat, Ivana Žagar, Jerca Blazina, Katarina Zevnik, Katica Bajuk-Studen, Katja Zaletel, Margareta Strojan Fležar, Marko Hočevar, Marko Kokalj, Marta Dremelj, Nebojša Glumac, Olga Blatnik, Simona Gaberšček, Snežana Pavlović Djokić, Ulrika Klopčič, Veronika Kloboves-Prevodnik, Zorica Čekić, 2022, professional article Keywords: rak ščitnice, diferencirani rak, zdravljenje, smernice Published in DiRROS: 01.07.2022; Views: 906; Downloads: 262 Full text (432,57 KB) |
25. Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe : an initiative of the Central European Cooperative Oncology Group (CECOG)Christiane Thallinger, Peter Berzinec, Emina Bicakcic, Adelina Dan, Gabriella Fabian, Laurentia Nicoletta Gales, Cvetka Grašič-Kuhar, Urška Janžič, Marina Mencinger, Christoph Zielinski, 2022, original scientific article Abstract: o establish a transborder virtual tumor board (VTB) fostering state-of-the-art management of cancer patients by exchanging knowledge and expertise among oncologists in Central and Southeastern Europe (CEE). Methods: We established and implemented a VTB based on the WebEx platform. This allowed for password-protected and secure upload of patient cases to be presented and discussed among colleagues from various oncology centers scattered throughout CEE in order to arrive at a recommendation for further diagnoses and/or treatment. Results: A total of 73 cases from 16 oncology centers located in 11 CEE countries were uploaded by 22 physicians; 71 were discussed over the course of 17 virtual meetings between June 2018 and May 2019 and 12 different kinds of malignant diseases were discussed with lung cancer (46.6%), melanoma (19.2%) and bladder cancer (13.6%) being the most commonly presented tumor entities. Of the discussed patients, 93.3% had stage IV disease at the time of presentation, 62.6% received chemotherapy or targeted treatment and 67.1% were treated with immune checkpoint inhibitors (ICPIs). The most common causes for presentation and discussion of patient cases were related to the use of ICPIs (80%). Conclusion: When the need for expertise exceeds locally available resources, web-based VTBs provide a feasible way to discuss patient cases and arrive at conclusions regarding diagnoses and/or treatment across large geographic distances. Moreover, VTBs provide an innovative way for proper, state-of-the-art management of patients with malignant diseases in times of social distancing and the resulting need for restricted interaction during the current SARS-CoV‑2 (severe acute respiratory syndrome coronavirus type 2) pandemic. Keywords: CECOG, Osrednja in jugovzhodna Evropa, nadzorni imunski zaviralci, maligne bolezni Published in DiRROS: 31.03.2022; Views: 781; Downloads: 447 Full text (1,14 MB) This document has many files! More... |
26. |
27. |
28. Učinkovitost in najpogostejši neželeni učinki zdravljenja z zaviralci od ciklina odvisnih kinaz 4 in 6 (CDK 4/6) pri metastatskem raku dojkeNina Privšek, Cvetka Grašič-Kuhar, 2021, other scientific articles Abstract: dZaviralci od ciklina odvisnih kinaz (CDK)4/6 so relativno nova tarčna zdravila pri raku dojk, ki jih uporabljamo pri hormonsko odvisnem HER-2 negativnem podtipu za bolnice z lokalno napredovalim ali razsejanim rakom. V registracijskih kliničnih raziskavah, kot tudi v vsakodnevni praksi, so se izkazali za učinkovita zdravila s sprejemljivim varnostnim profilom. V spodnjem prispevku bomo na kratko predstavili učinkovitost in najpogostejše neželene učinke zdravljenja z zaviralci CDK4/6 ter ukrepanje ob njihovem pojavu. Keywords: zaviralci CDK4/6, palbociklib, ribociklib, abemaciklib, neželeni učinki Published in DiRROS: 14.12.2021; Views: 1046; Downloads: 298 Full text (158,51 KB) |
29. Učinkovitost (in varnost) cepljenja onkoloških bolnikov proti covidu-19 med aktivnim zdravljenjemTina Zupančič, Cvetka Grašič-Kuhar, 2021, other scientific articles Abstract: Onkološki bolniki so bili že ob začetku pandemije covida-19 prepoznani kot skupina s povečanim tveganjem zapletov ob morebitni okužbi z virusom SARS-CoV-2, vendar so bili izključeni iz registracijskih raziskav cepiv proti covidu-19. Šele v zadnjih mesecih imamo na voljo več raziskav, ki so preučevale učinkovitost cepljenja pri onkoloških bolnikih z različnimi načini zdravljenja. Te so pokazale dobro učinkovitost (tako z razvojem humoralnega kot celičnega odgovora) in varnost cepiv predvsem pri bolnikih s solidnimi raki. Pričakovano slabši humoralni odziv je bil pri hematoloških bolnikih oziroma ga skoraj ni bilo pri bolnikih na terapiji anti-CD20 in terapiji z zaviralci Brutonove kinaze. Vendar je bil pri hematoloških bolnikih ohranjen celični odgovor in tako je smiselno cepljenje tudi pri tej skupini bolnikov, tudi s tretjim odmerkom. Pri bolnikih, ki so predhodno preboleli okužbo s SARS-CoV-2 ter bili nato cepljeni, so ugotavljali bistveno boljši humoralni odgovor kot pri cepljenju neprebolevnikov. Keywords: cepljenje, onkološki bolniki, covid-19, humoralni odgovor, celični odgovor Published in DiRROS: 14.12.2021; Views: 1072; Downloads: 455 Full text (119,90 KB) This document has many files! More... |
30. Timski pristop k zdravljenju raka glave in vratuPrimož Strojan, Cvetka Grašič-Kuhar, Branko Zakotnik, 2020, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: timska obravnava, stranski učinki, bolniki, zdravstveni nasveti Published in DiRROS: 18.10.2021; Views: 988; Downloads: 326 Full text (1,02 MB) |